Results 231 to 240 of about 87,039 (290)

HUSM endocarditis team's approach to acute ruptured chordae tendineae in chronic rheumatic heart disease. [PDF]

Clin Case Rep
Othman MK, Abdullahilhai AA, Yusof Z, W Isa WYH, Muhd Besari Hashim A, Mokhtar AM, Hussain AH, Hassan MH, Mamat AZ.   +8 more
europepmc   +1 more source

A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Abstract Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials, mainly due to the scarcity of available trial participants and the heterogeneity of disease progression. A quantitative clinical trial simulator (CTS) has been developed based on previously published five disease ...
Jordan Wilk, Varun Aggarwal, Mike Pauley, Diane Corey, Daniela J. Conrado, Karthik Lingineni, Juan Francisco Morales, Deok Yong Yoon, Yi Zhang, Zihan Cui, Jackson Burton, Jane Larkindale, Shu Chin Ma, Collin Hovinga, Terina Martinez, Klaus Romero, Ramona Belfiore‐Oshan, Sarah Kim, the Duchenne Regulatory Science Consortium (D‐RSC) and the CINRG DNHS investigators   +18 more
wiley   +1 more source

Rwanda RHD Research Network: Central Hub for International Collaborative Efforts to Tackle Rheumatic Heart Disease. [PDF]

JACC Adv
Mukeshimana G, Marchandot B, Mutabazi V, Lazeras C, Nsengiyumva C, Anh Mai T, Nguyen QN, Pham HM, Pibarot P, Morel O, Rwanda RHD Research Network.   +10 more
europepmc   +1 more source

Predictors of systemic sclerosis patients with interstitial lung disease progression: A retrospective study

Rheumatology &Autoimmunity, EarlyView.
The final systemic sclerosis patients with interstitial lung disease (SSc‐ILD) progression prediction model was composed of 6 significant risk factors: male, type 2 diabetes mellitus, pericardial effusion, anti‐Ro52, hypoproteinemia, and elevated C‐reactive protein. Our model demonstrated excellent prognostic utility.
Xi Cao, Shanshan Wang, Wenyi Yuan, Mian Liu, Xiaoyan Xin, Xiang Fang, Dandan Wang   +6 more
wiley   +1 more source

Mortality and Morbidity in Adults With Rheumatic Heart Disease.

JAMA
Karthikeyan G, Ntsekhe M, Islam S, Rangarajan S, Avezum A, Benz A, Cabral TTJ, Changsheng M, Chillo P, Gonzalez-Hermosillo JA, Gitura B, Damasceno A, Dans AML, Davletov K, Elghamrawy A, ElSayed A, Fana GT, Gondwe L, Haileamlak A, Kayani AM, Lwabi P, Maklady F, Molefe-Baikai OJ, Musuku J, Ogah OS, Paniagua M, Rusingiza E, Sharma SK, Zuhlke L, Connolly S, Yusuf S, INVICTUS Investigators.   +31 more
europepmc   +1 more source

Living with rheumatic fever and rheumatic heart disease in Victoria, Australia: A qualitative study. [PDF]

PLoS Negl Trop Dis
Oliver J, Fualautoalasi-Lam L, Ferdinand A, Tiatia R, Jones B, Engelman D, Gibney KB, Steer AC.   +7 more
europepmc   +1 more source

How pandemics reshape our brain: Common links and targets between long‐haul COVID‐19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), oxidative stress, and neurodegeneration

Neuroprotection, EarlyView.
Mary E. Herman
wiley   +1 more source

Unveiling End-of-Life Disparities in Chronic Rheumatic Heart Disease: A 22-Year Analysis of the CDC-WONDER Database. [PDF]

Cureus
Khanal A, Rao NL, Rajaravichandran A, Pathil AA, Majumder K, Rodriguez J.   +5 more
europepmc   +1 more source

Assessing the evidence for antibiotic management of laboratory-confirmed <i>Streptococcus A</i> skin infections to prevent acute rheumatic fever and rheumatic heart disease: a systematic review. [PDF]

IJID Reg
Leong TD, Hohlfeld AS, Bango F, Mabetha D, Blose N, Oliver J, Engel ME, Kredo T.   +7 more
europepmc   +1 more source